- Market Capitalization, $K 139,759,584
- Shares Outstanding, K 2,624,593
- Annual Sales, $ 24,384 M
- Annual Income, $ 1,335 M
- 60-Month Beta 0.55
- Price/Sales 5.40
- Price/Cash Flow 16.59
- Price/Book 10.13
|Period||Period Low||Period High||Performance|
| || |
+4.52 (+9.28%)since 12/22/20
| || |
+1.29 (+2.48%)since 10/22/20
| || |
+2.80 (+5.55%)since 01/22/20
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Alexion Pharmaceuticals, Inc. (NasdaqGS: ALXN)...
Moderna's (MRNA) partner Takeda doses the first participant in a phase I/II study with Moderna's coronavirus vaccine candidate, mRNA-1273 in Japan.
Merck (MRK), Glaxo (GSK), AstraZeneca (AZN) and J&J (JNJ) announce FDA approvals.
, /PRNewswire/ -- Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and...
AstraZeneca's (AZN) Enhertu gets EU approval for metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens.
Astrazeneca (AZN) closed the most recent trading day at $52.24, moving -0.63% from the previous trading session.
Gritstone (GRTS) will develop a second generation vaccine candidate against COVID-19 with the potential for both prolonged protection and potency against spike mutants of the virus. Stock rises.
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BABA, GE, AZN, NIO, and BLNK.
Grifols (GRFS) to begin a study in Spain to evaluate a plasma-derived medicine that would provide immediate immunity against COVID-19.
AstraZeneca's (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.
|Value Line Dividend Idx ETF FT|
|Pharmaceutical Vaneck ETF|
|Nasdaq Biotechnology Ishares ETF|
|Ai Powered International Equity ETF|
|Jpmorgan Betabuilders Europe ETF|
|3rd Resistance Point||54.57|
|2nd Resistance Point||54.06|
|1st Resistance Point||53.65|
|1st Support Level||52.73|
|2nd Support Level||52.22|
|3rd Support Level||51.81|